$TNGX
Tango Therapeutics, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022004721 Filed on March 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $5.758M $5.716M $37.04M
YoY Change -9.83% 383.83%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.807M $6.066M $17.60M
YoY Change 2459.98% 4970.63% 9598.51%
% of Gross Profit
Research & Development $24.33M $21.63M $77.64M
YoY Change 62.2% 55.3%
% of Gross Profit
Depreciation & Amortization $300.0K $256.0K $900.0K
YoY Change 50.0% 28.57%
% of Gross Profit
Operating Expenses $31.14M $27.70M $95.23M
YoY Change 68.61% 23634.04% 59.1%
Operating Profit -$25.38M -$58.19M
YoY Change 110.07% 11.48%
Interest Expense $218.0K $196.0K $495.0K
YoY Change 717.4% 267.11% 658.62%
% of Operating Profit
Other Income/Expense, Net $171.0K -$81.00K $247.0K
YoY Change 248.98% 8.33%
Pretax Income -$25.21M -$21.87M -$57.94M
YoY Change 109.51% 34437.27% 11.49%
Income Tax $0.00 $177.0K $300.0K
% Of Pretax Income
Net Earnings -$25.21M -$22.05M -$58.24M
YoY Change 108.23% 31313.51% 12.05%
Net Earnings / Revenue -437.79% -385.69% -157.21%
Basic Earnings Per Share -$0.29 -$0.94
Diluted Earnings Per Share -$287.5K -$249.8K -$937.6K
COMMON SHARES
Basic Shares Outstanding 87.71M 87.55M 62.11M
Diluted Shares Outstanding 87.67M 62.11M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $449.9M $485.3M $485.3M
YoY Change 35648.85% 154.97% 36827.08%
Cash & Equivalents $99.91M $142.7M $142.7M
Short-Term Investments $350.0M $342.5M $342.5M
Other Short-Term Assets $8.769M $5.083M $5.083M
YoY Change 4447.53% 2670.03% 2670.03%
Inventory
Prepaid Expenses
Receivables $2.000M $2.000M $2.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $460.7M $492.3M $492.3M
YoY Change 31641.22% 154.26% 32775.57%
LONG-TERM ASSETS
Property, Plant & Equipment $6.538M $4.832M $6.086M
YoY Change 26.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $16.00K $19.00K $1.731M
YoY Change -50.0%
Total Long-Term Assets $10.87M $7.817M $7.817M
YoY Change -93.48% -42.61% -95.31%
TOTAL ASSETS
Total Short-Term Assets $460.7M $492.3M $492.3M
Total Long-Term Assets $10.87M $7.817M $7.817M
Total Assets $471.5M $500.2M $500.2M
YoY Change 180.23% 141.33% 197.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.367M $3.226M $3.226M
YoY Change 4828.28% 75.23%
Accrued Expenses $10.77M $11.39M $11.39M
YoY Change 4659.34% 10496.33% 10496.33%
Deferred Revenue $25.02M $26.02M
YoY Change -18.62%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.21M $40.69M $40.69M
YoY Change 12885.49% -0.55% 35483.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $112.0M $114.7M $114.7M
YoY Change 1818.32% 2294260.0% 1865.61%
Total Long-Term Liabilities $112.0M $114.7M $114.7M
YoY Change 1818.32% 2294260.0% 1865.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.21M $40.69M $40.69M
Total Long-Term Liabilities $112.0M $114.7M $114.7M
Total Liabilities $151.2M $155.4M $155.4M
YoY Change 2362.75% -7.85% 2511.64%
SHAREHOLDERS EQUITY
Retained Earnings -$186.5M -$161.3M
YoY Change 56.48%
Common Stock $88.00K $88.00K
YoY Change 120.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $320.4M $344.7M $344.7M
YoY Change
Total Liabilities & Shareholders Equity $471.5M $500.2M $500.2M
YoY Change 180.23% 141.33% 197.16%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$25.21M -$22.05M -$58.24M
YoY Change 108.23% 31313.51% 12.05%
Depreciation, Depletion And Amortization $300.0K $256.0K $900.0K
YoY Change 50.0% 28.57%
Cash From Operating Activities -$29.67M -$16.90M -$59.53M
YoY Change 117.92% 6997.51% -184.95%
INVESTING ACTIVITIES
Capital Expenditures $1.561M -$696.0K $1.837M
YoY Change 846.06% 66.09%
Acquisitions
YoY Change
Other Investing Activities -$10.16M -$44.51M -$181.6M
YoY Change -454092.5%
Cash From Investing Activities -$11.72M -$45.21M -$183.4M
YoY Change -156.85% 26.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 257.0K -120.0K 357.3M
YoY Change -99.15% 341.77%
NET CHANGE
Cash From Operating Activities -29.67M -16.90M -59.53M
Cash From Investing Activities -11.72M -45.21M -183.4M
Cash From Financing Activities 257.0K -120.0K 357.3M
Net Change In Cash -41.13M -62.23M 114.4M
YoY Change -209.93% 26031.27% 1982.37%
FREE CASH FLOW
Cash From Operating Activities -$29.67M -$16.90M -$59.53M
Capital Expenditures $1.561M -$696.0K $1.837M
Free Cash Flow -$31.23M -$16.21M -$61.36M
YoY Change 126.64% -188.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001819133
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39485
CY2021 dei Entity Registrant Name
EntityRegistrantName
TANGO THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1195036
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Binney St.
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2021 dei City Area Code
CityAreaCode
857
CY2021 dei Local Phone Number
LocalPhoneNumber
320-4900
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
TNGX
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
189800000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
87707499
CY2021 dei Auditor Firm
AuditorFirmId
238
CY2021 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142745000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28381000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
342510000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
161939000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
567000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4516000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1312000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
492338000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
193632000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4832000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3823000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1254000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7480000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1712000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2279000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
38000
CY2021Q4 us-gaap Assets
Assets
500155000
CY2020Q4 us-gaap Assets
Assets
207252000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3226000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1841000
CY2021Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9887000
CY2020Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6140000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1503000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
959000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
26022000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31977000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
52000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40690000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40917000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6925000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
114718000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
120805000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5000
CY2021Q4 us-gaap Liabilities
Liabilities
155408000
CY2020Q4 us-gaap Liabilities
Liabilities
168652000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
56393261
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87598184
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87598184
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40372133
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40372133
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
88000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
40000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
506760000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
141644000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-765000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-161336000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103101000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
344747000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
38600000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
500155000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207252000
CY2021 us-gaap Revenues
Revenues
37042000
CY2020 us-gaap Revenues
Revenues
7656000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77636000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49991000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17596000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9865000
CY2021 us-gaap Operating Expenses
OperatingExpenses
95232000
CY2020 us-gaap Operating Expenses
OperatingExpenses
59856000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-58190000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-52200000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
495000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
108000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-248000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
120000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
247000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
228000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57943000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51972000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
292000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58235000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-51972000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62108032
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31932204
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58235000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-51972000
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-782000
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
7000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59017000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51965000
CY2019Q4 tngx Stock Holders Equity Before Retroactive Application Of Recapitalization
StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization
-47795000
CY2019Q4 tngx Stock Holders Equity Retroactive Application Of Recapitalization
StockHoldersEquityRetroactiveApplicationOfRecapitalization
55700000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7905000
CY2020 tngx Retroactive Application Of Recapitalization
RetroactiveApplicationOfRecapitalization
29761000
CY2020 tngx Retroactive Application Of Recapitalization One
RetroactiveApplicationOfRecapitalizationOne
51083000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
12000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1764000
CY2020 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
7000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-51972000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
38600000
CY2021 tngx Retroactive Application Of Recapitalization
RetroactiveApplicationOfRecapitalization
29990000
CY2021 tngx Stock Issued During Period Value Acquisitions And Private Investments
StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments
326277000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1058000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
6000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7833000
CY2021 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-782000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58235000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
344747000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58235000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-51972000
CY2021 us-gaap Depreciation
Depreciation
897000
CY2020 us-gaap Depreciation
Depreciation
718000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1069000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
907000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
7833000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1764000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-254000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
17000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2000000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3159000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
81000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
139000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
38000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1232000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1171000
CY2021 tngx Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
3829000
CY2020 tngx Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
1196000
CY2021 tngx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1066000
CY2020 tngx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-655000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12042000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
119081000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59527000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
70074000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1837000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1106000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
190764000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
63220000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
372361000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
207540000
CY2020 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
40000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-183434000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-145466000
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
29990000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
80844000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1058000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
40000
CY2021 tngx Proceeds From Business Combination And Pipe Financing Gross
ProceedsFromBusinessCombinationAndPipeFinancingGross
342113000
CY2021 tngx Payment Of Business Combination And Pipe Financing Transaction Costs
PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts
15836000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
357325000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80884000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
114364000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5492000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30660000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25168000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145024000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30660000
CY2021 tngx Cash Paid For Leases
CashPaidForLeases
-1835000
CY2020 tngx Cash Paid For Leases
CashPaidForLeases
-1782000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
166534000
CY2021 tngx Revaluation Of Right Of Use Asset And Lease Liability Upon Lease Modification
RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification
5315000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
154000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000
CY2020Q3 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
5800000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Significant Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents and marketable debt securities. The Company’s cash, cash equivalent and marketable securities balances are held by major financial institutions that management believes to be creditworthy. The Company uses multiple financial institutions to limit the amount of credit exposure to any one financial institution. Substantially all the Company’s cash, cash equivalent and marketable debt securities were invested in money market funds, U.S. Treasury bills, and U.S. government agency bonds at December 31, 2021 and 2020. At times, the Company’s cash deposits may exceed the amount of federal insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company relies, and expects to continue to rely, on a small number of vendors to perform research activities and clinical trial activities that continue to progress its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the related processes of these vendors.</span>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
2300000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
2300000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142745000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28381000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
567000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1712000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2279000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
145024000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30660000
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
14000000.0
CY2021Q4 tngx Receivable Research Extension Fee
ReceivableResearchExtensionFee
24000000.0
CY2021Q4 tngx Accounts Receivable Current Research Extension Fee
AccountsReceivableCurrentResearchExtensionFee
2000000.0
CY2021Q4 tngx Contractassetresearchextensionfee
Contractassetresearchextensionfee
8000000.0
CY2021 tngx Expected Dividend Assumed
ExpectedDividendAssumed
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87474239
CY2021Q3 tngx Stock Issued During Period Shares In Exchange For Unvested Restricted Stock Awards And Unexercised Stock Options
StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions
6406197
CY2021Q3 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2021Q3 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2021Q4 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2020Q4 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2021Q3 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2020 tngx Weighted Average Recapitalized Common Shares
WeightedAverageRecapitalizedCommonShares
3893305
CY2020 tngx Conversion Weightage Percentage
ConversionWeightagePercentage
1
CY2020 tngx Weighted Average Number Of Share Outstanding Basic And Diluted Adjustments
WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments
3893305
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31932204
CY2021Q4 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2020Q4 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P5Y7M6D
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
161939000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7361000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5507000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2529000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1684000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4832000
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
343275000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
766000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
342510000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
161922000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
17000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3823000
CY2021 us-gaap Depreciation
Depreciation
900000
CY2020 us-gaap Depreciation
Depreciation
700000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3688000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2652000
CY2021Q4 tngx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5533000
CY2020Q4 tngx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2695000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
666000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
793000
CY2021Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9887000
CY2020Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6140000
CY2019Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
option to extend for up to two five-year periods.
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1300000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7500000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1889000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1889000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
133000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
93000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
673000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
643000
CY2021 us-gaap Lease Cost
LeaseCost
2695000
CY2020 us-gaap Lease Cost
LeaseCost
2625000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1835000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1782000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1572000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1572000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
69000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1503000
CY2017Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
4700000
CY2021Q4 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
0.34
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holder of each share of common stock is entitled to one vote in respect of each share of stock held.
CY2021Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
638754
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.66
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
283638
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.34
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9372993
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.59
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87598184
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87598184
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40372133
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40372133
CY2021Q4 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4094544
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.88
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M29D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6635627000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6200841
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
51415394000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2117654
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.56
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M7D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
17759485000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.72
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.67
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.72
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.005
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.004
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30945000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1114000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2640000
CY2021Q4 tngx Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
771000
CY2020 tngx Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.044
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.011
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7833000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1764000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.061
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059
CY2021 tngx Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.054
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.006
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.321
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.289
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.004
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4403000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11085000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7084000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5213000
CY2021Q4 tngx Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
411000
CY2020Q4 tngx Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2154000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
34625000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11891000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
958000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
648000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2193000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2506000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1008000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
88000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50682000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33585000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49568000
CY2020Q4 tngx Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
597000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
343000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
2043000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1114000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2640000
CY2021Q4 tngx Percentage Of Increase In Ownership Percentage Over A Three Year Period
PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod
0.50
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18600000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58235000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-51972000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62108032
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31932204
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9372993
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4353375

Files In Submission

Name View Source Status
0000950170-22-004721-index-headers.html Edgar Link pending
0000950170-22-004721-index.html Edgar Link pending
0000950170-22-004721.txt Edgar Link pending
0000950170-22-004721-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img158215518_0.jpg Edgar Link pending
img158215518_1.jpg Edgar Link pending
img158215518_10.jpg Edgar Link pending
img158215518_11.jpg Edgar Link pending
img158215518_12.jpg Edgar Link pending
img158215518_13.jpg Edgar Link pending
img158215518_14.jpg Edgar Link pending
img158215518_15.jpg Edgar Link pending
img158215518_16.jpg Edgar Link pending
img158215518_17.jpg Edgar Link pending
img158215518_18.jpg Edgar Link pending
img158215518_19.jpg Edgar Link pending
img158215518_2.jpg Edgar Link pending
img158215518_20.jpg Edgar Link pending
img158215518_3.jpg Edgar Link pending
img158215518_4.jpg Edgar Link pending
img158215518_5.jpg Edgar Link pending
img158215518_6.jpg Edgar Link pending
img158215518_7.jpg Edgar Link pending
img158215518_8.jpg Edgar Link pending
img158215518_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tngx-20211231.htm Edgar Link pending
tngx-20211231.xsd Edgar Link pending
tngx-20211231_cal.xml Edgar Link unprocessable
tngx-20211231_def.xml Edgar Link unprocessable
tngx-20211231_htm.xml Edgar Link completed
tngx-20211231_lab.xml Edgar Link unprocessable
tngx-20211231_pre.xml Edgar Link unprocessable
tngx-ex10_14.htm Edgar Link pending
tngx-ex23_1.htm Edgar Link pending
tngx-ex31_1.htm Edgar Link pending
tngx-ex31_2.htm Edgar Link pending
tngx-ex32_1.htm Edgar Link pending
tngx-ex32_2.htm Edgar Link pending
tngx-ex4_2.htm Edgar Link pending